Last reviewed · How we verify
volume replacement
Volume replacement restores circulating blood volume through administration of fluids or blood products to treat hypovolemia and maintain hemodynamic stability.
Volume replacement restores circulating blood volume through administration of fluids or blood products to treat hypovolemia and maintain hemodynamic stability. Used for Acute blood loss and hemorrhagic shock, Severe dehydration and hypovolemic shock, Perioperative fluid management.
At a glance
| Generic name | volume replacement |
|---|---|
| Also known as | Voluven, HES 130/0.4 |
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Volume replacement is a supportive therapeutic approach rather than a drug with a specific molecular mechanism. It involves infusion of crystalloid solutions, colloids, or blood products to restore intravascular volume lost through hemorrhage, dehydration, or third-spacing. This restores cardiac preload, maintains tissue perfusion, and prevents shock.
Approved indications
- Acute blood loss and hemorrhagic shock
- Severe dehydration and hypovolemic shock
- Perioperative fluid management
- Burn management and fluid resuscitation
Common side effects
- Fluid overload / pulmonary edema
- Electrolyte imbalance
- Hypothermia (from room-temperature fluids)
- Transfusion reactions (if blood products used)
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Impact of Pleth Variability Index-Guided Acute Normovolemic Hemodilution on Intraoperative Fluid Management and Postoperative Complications in Cardiac Surgery (NA)
- Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function (NA)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Comparison of Mastectomy Expander Trial (NA)
- Restrictive Fluid Management In Liver Transplantation (REFIL) (NA)
- Does Early Postoperative Fluid Management Affect Functional Delayed Graft Function After Living Donor Kidney Transplantation?
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- volume replacement CI brief — competitive landscape report
- volume replacement updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI